New cervical cancer screening strategy: Combined Pap and HPV testing

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 2, 2005, Pages 141-148

  Jin, Xian Wen ^a   Zanotti, Kristine ^a   Yen Lieberman, Belinda ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P16INK4A; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

AGE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONDYLOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DRUG EFFICACY; FEMALE; HIGH RISK POPULATION; HUMAN; PAPANICOLAOU TEST; PATIENT COUNSELING; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINE PRODUCTION; VIRUS CARCINOGENESIS; VIRUS DETECTION; WART VIRUS; ADULT; AGED; ARTICLE; COLPOSCOPY; ISOLATION AND PURIFICATION; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PAPILLOMA VIRUS; RISK FACTOR; STANDARD; UTERINE CERVIX TUMOR; UTILIZATION REVIEW; VAGINA SMEAR; VIROLOGY; VIRUS INFECTION;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 17844370547     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.2.141     Document Type: Review

References (60)

1. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004; 103:304-309.
2. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol 2003; 102:417-427.
3. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52:342-362.
4. US Preventive Services Task Force. Guide to Clinical Preventive Services: Periodic Updates. 3rd ed. Washington, DC: US Department of Health and Human Services; 2003.
5. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287:2120-2129.
6. Hutchinson ML, Agarwal P, Denault T, Berger B, Cibas ES. A new look at cervical cytology. ThinPrep multicenter trial results. Acta Cytol 1992; 36:499-504.
7. Lee KR, Ashfaq R, Birdsong GG, Corkill ME, McIntosh KM, Inhorn SL. Comparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening. Obstet Gynecol 1997; 90:278-284.
8. Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol 2001; 185:308-317.
9. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114-2119.
10. Stoler MH. New Bethesda terminology and evidence-based management guidelines for cervical cytology findings. JAMA 2002; 287:2140-2141.
11. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000; 92:397-402.
12. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001; 93:293-299.
13. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285:1500-1505.
14. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992; 79:328-337.
15. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796-802.
16. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19.
17. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92:464-474.
18. Thomas DB, Qin Q, Kuypers J, et al. Human papillomaviruses and cervical cancer in Bangkok. II. Risk factors for in situ and invasive squamous cell cervical carcinomas. Am J Epidemiol 2001; 153:732-739.
19. de Villiers EM. Taxonomic classification of papillomaviruses. Papillomavirus Rep 2001; 12:57-63.
20. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527.
21. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-265.
22. Lancaster WD, Castellano C, Santos C, Delgado G, Kurman RJ, Jenson AB. Human papillomavirus deoxyribonucleic acid in cervical carcinoma from primary and metastatic sites. Am J Obstet Gynecol 1986; 154:115-119.
23. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. Embo J 1984; 3:1151-1157.
24. Schlegel R. Papillomaviruses and human cancer. Semin Virol 1990; 1:297-306.
25. zur Hausen H, de Villiers EM. Human papillomaviruses. Annu Rev Microbiol 1994; 48:427-447.
26. Scheffner M, Romanczuk H, Munger K, Huibregtse JM, Mietz JA, Howley PM. Functions of human papillomavirus proteins. Curr Top Microbiol Immunol 1994; 186:83-99.
27. Arbeit JM, Munger K, Howley PM, Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 1994; 68:4358-4368.
28. Greenhalgh DA, Wang XJ, Rothnagel JA, et al. Transgenic mice expressing targeted HPV-18 E6 and E7 oncogenes in the epidermis develop verrucous lesions and spontaneous, rasHa-activated papillomas. Cell Growth Differ 1994; 5:667-675.
29. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science Apr 6 1990; 248(4951):76-79.
30. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75:495-505.
31. Havre PA, Yuan J, Hedrick L, Cho KR, Glazer PM. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res 1995; 55:4420-4424.
32. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. Embo J 1989; 8:4099-4105.
33. Duensing S, Lee LY, Duensing A, et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci USA 2000; 97:10002-10007.
34. Richart RM, Cox JT, Kinney WK, Stoler MH. Combined HPV and Pap testing: advances in risk assessment. Contemp Obstet Gynecol 2003; April:4S-16S.
35. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132:810-819.
36. Bastian L, Datta S, Hasselblad V, et al. Evaluation of cervical cytology, 5. Agency for Health Care Policy and Research. http://hstat.nlm.nih.gov/hq/hquest/db/local.epc.er.cyt/screen/doc-title/s /48139. Accessed February 25, 2003.
37. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995; 141:680-689.
38. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002; 288:1749-1757.
39. Zielinski GD, Snijders PJ, Rozendaal L, et al. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 2001; 85:398-404.
40. Allen KA, Zaleski S, Cohen MB. Review of negative Papanicolaou tests. Is the retrospective 5-year review necessary? Am J Clin Pathol 1994; 101:19-21.
41. Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003; 127:959-968.
42. Salmeron J, Lazcano-Ponce E, Lorincz A, et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 2003; 14:505-512.
43. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001; 83:439-444.
44. Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000; 283:81-86.
45. Petry KU, Menton S, Menton M, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003; 88:1570-1577.
46. Sherman ME, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst 2002; 94:102-107.
47. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer 2000; 88:2283-2289.
48. Pinto AP, Crum CP. Natural history of cervical neoplasia: defining progression and its consequence. Clin Obstet Gynecol 2000; 43:352-362.
49. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003; 348:489-490.
50. Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325:572.
51. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003; 95:46-52.
52. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993; 85:958-964.
53. Fairley CK, Chen S, Tabrizi SN, Leeton K, Quinn MA, Garland SM. The absence of genital human papillomavirus DNA in virginal women. Int J STD AIDS 1992; 3:414-417.
54. Schiffman M, Kjaer SK. Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 31:14-19.
55. Rubin MA, Kleter B, Zhou M, et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 2001; 159:1211-1218.
56. Franceschi S, Castellsague X, Dal Maso L, et al. Prevalence and determinants of human papillomavirus genital infection in men. Br J Cancer 2002; 86:705-711.
57. Keating JT, Ince T, Crum CP. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 2001; 8:83-92.
58. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153:1741-1748.
59. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-1651.
60. Crum CP, Rivera MN. Vaccines for cervical cancer. Cancer J 2003; 9:368-376.